trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Ibrutinib is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Ibrutinib is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease?

Yes. Ibrutinib is a targeted Bruton's tyrosine kinase inhibitor widely indicated and approved for several B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenström's macroglobulinemia, as well as chronic graft-versus-host disease.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved papers and medical literature widely support the usage and indications of ibrutinib across the stated hematologic malignancies and immune-mediated conditions.

Evidence for · 3
Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma
2023
Get citation
Pınar, İ. E. & Ozkocaman, V. (2023). Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma. doi.org. https://doi.org/10.18621/eurj.1359362

See more details
More for · 2
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
2023
Get citation
Shadman, M., Flinn, I. W., Levy, M. Y., Porter, R. F., Burke, J. M., Zafar, S. F., Misleh, J., Kingsley, E. C., Yimer, H. A., Freeman, B., Rao, S. S., Chaudhry, A., Tumula, P. K., Gandhi, M. D., Manda, S., Chen, D., By, K., Xu, L., Liu, Y., Crescenzo, R., Idoine, A., Zhang, X., Cohen, A., Huang, J., & Sharman, J. P. (2023). Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.. doi.org. https://doi.org/10.1016/S2352-3026(22)00320-9

Zanubrutinib: past, present, and future.
2023
Get citation
Tam, C. S., Muñoz, J. L., Seymour, J. F., & Opat, S. (2023). Zanubrutinib: past, present, and future.. doi.org. https://doi.org/10.1038/s41408-023-00902-x

What does the evidence say?

The retrieved papers and medical literature widely support the usage and indications of ibrutinib across the stated hematologic malignancies and immune-mediated conditions.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work